Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of New Mexico
This is a study of chemoradiation for patient with inoperable non small cell lung cancer with poor pulmonary function. These patients have usually very limited treatment options because of the compromised lung function. Chemoradiation is usually superior to radiation alone, but has not been extensively tested in this patient population. Topotecan is a drug approved for lung cancer that has synergistic activity with radiation. The study will determine what is the safest dose of topotecan to use with radiation in this patient population
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically proven non-small cell lung cancer Stage I to IIIA.
Inoperable lung cancer because of poor respiratory lung function, or other medical reasons, as determined by the thoracic surgeon.
PS \< 2
Age \> 18 years
Life expectancy of \> 12 weeks
Normal hematologic, liver, and renal function
No metastatic disease as determined by CT-PET scanning and bone scan.
No brain metastasis by MRI
No contraindication to radiotherapy
You may not be if
Patients with uncontrolled CNS metastases.
Active systemic infection.
Serious, uncontrolled intercurrent medical or psychiatric illness.
Secondary active primary malignancy.
Inability to comply with requirements of the study.
Any metastases outside of the mediastinum
Histologically positive pleural or pericardial effusion
Any chemotherapy within five years prior to enrollment on this protocol
Prior radiotherapy administered to the chest
Women who are pregnant or lactating
FEV1 \< 1 liter/minute
Clareo Health | Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer
